{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,26]],"date-time":"2026-10-26T04:34:26Z","timestamp":1792989266475,"version":"4.5.0"},"reference-count":38,"publisher":"Wiley","issue":"10","license":[{"start":{"date-parts":[[2026,10,4]],"date-time":"2026-10-04T00:00:00Z","timestamp":1791072000000},"content-version":"vor","delay-in-days":3,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"},{"start":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T00:00:00Z","timestamp":1790812800000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/doi.wiley.com\/10.1002\/tdm_license_1.1"}],"content-domain":{"domain":["onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["Medical Journal of Australia"],"published-print":{"date-parts":[[2026,10]]},"abstract":"<jats:title>ABSTRACT<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Objectives<\/jats:title>\n                    <jats:p>To analyse the extent and patterns of pharmaceutical industry funding of patient groups in Australia between 2013 and 2022, including the proportion of groups' income derived from industry payments in 2022.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Study Type<\/jats:title>\n                    <jats:p>Longitudinal observational study.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Setting, Participants<\/jats:title>\n                    <jats:p>Australia, 1 January 2013\u201331 December 2022. Public disclosures of payments to patient groups from pharmaceutical companies who were members of Medicines Australia (the trade organisation for the prescription pharmaceutical industry in Australia) between 2013 and 2022 and from non\u2010member companies with at least five registered prescription products in Australia.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Main Outcome Measures<\/jats:title>\n                    <jats:p>Value (in Australian dollars) of reported payments to patient groups from the pharmaceutical industry and trends in payments by clinical area and over time. For patient groups that received industry funding in 2022, we also examined how this compared with their total income for that year.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>Between 2013 and 2022, 45 pharmaceutical companies disclosed $95.7 million in funding to 390 patient groups. Funding was highly skewed, with 13 groups receiving 47.9% ($45,856,940\/$95,724,493) of the total payments. The median funding over the decade was $34,374 (interquartile range [IQR], $8228\u2013$122,898) per group. The total reported payments decreased by $293,246 (95% confidence interval, $125,489\u2013$461,006) per year, but some clinical areas, such as oncology, saw an increase. For groups that received funding in 2022, the median proportion of income derived from industry was 2.2% (IQR, 0.3%\u20139.3%) and nine groups had over half their income from industry.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>Industry funding of patient groups was widespread but skewed towards a small subset of groups and clinical areas. This may shift the focus of advocacy efforts towards certain conditions that align with current industry interests. Although further research is still needed on links between funding and patient group priorities, current disclosure measures may be insufficient to manage risks and access to other funding sources and additional safeguards may be needed to maintain independence.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.5694\/mja2.70294","type":"journal-article","created":{"date-parts":[[2026,10,4]],"date-time":"2026-10-04T13:02:19Z","timestamp":1791118939000},"update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Pharmaceutical Industry Payments to Patient Groups in Australia: A Longitudinal Analysis of a Decade of Disclosures"],"prefix":"10.5694","volume":"224","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-8526-1837","authenticated-orcid":false,"given":"Ashleigh","family":"Hooimeyer","sequence":"first","affiliation":[{"name":"Charles Perkins Centre, University of Sydney  Sydney New South Wales Australia"},{"name":"Faculty of Medicine and Health Sydney Pharmacy School, University of Sydney  Sydney New South Wales Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3744-2219","authenticated-orcid":false,"given":"Annim","family":"Mohammad","sequence":"additional","affiliation":[{"name":"Faculty of Medicine and Health Sydney Pharmacy School, University of Sydney  Sydney New South Wales Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8413-0440","authenticated-orcid":false,"given":"Alice","family":"Fabbri","sequence":"additional","affiliation":[{"name":"Department for Health University of Bath  Bath UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8635-6953","authenticated-orcid":false,"given":"Lisa","family":"Parker","sequence":"additional","affiliation":[{"name":"Charles Perkins Centre, University of Sydney  Sydney New South Wales Australia"},{"name":"Faculty of Medicine and Health Northern Clinical School, University of Sydney  Sydney New South Wales Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4358-6641","authenticated-orcid":false,"given":"Kellia","family":"Chiu","sequence":"additional","affiliation":[{"name":"Charles Perkins Centre, University of Sydney  Sydney New South Wales Australia"},{"name":"Faculty of Medicine and Health Sydney Pharmacy School, University of Sydney  Sydney New South Wales Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8671-915X","authenticated-orcid":false,"given":"Barbara","family":"Mintzes","sequence":"additional","affiliation":[{"name":"Charles Perkins Centre, University of Sydney  Sydney New South Wales Australia"},{"name":"Faculty of Medicine and Health Sydney Pharmacy School, University of Sydney  Sydney New South Wales Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2026,10,4]]},"reference":[{"key":"e_1_2_10_2_1","volume-title":"Conversations for Change Report: Improving Consumer Engagement in Health Technology Assessment","author":"Australian Government Department of Health and Aged Care","year":"2023"},{"key":"e_1_2_10_3_1","doi-asserted-by":"publisher","DOI":"10.1177\/2168479017706405"},{"key":"e_1_2_10_4_1","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0235021"},{"key":"e_1_2_10_5_1","doi-asserted-by":"publisher","DOI":"10.1111\/1467-9566.13409"},{"key":"e_1_2_10_6_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.healthpol.2022.11.003"},{"key":"e_1_2_10_7_1","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.l1806"},{"key":"e_1_2_10_8_1","doi-asserted-by":"publisher","DOI":"10.1136\/bmjopen-2022-071138"},{"key":"e_1_2_10_9_1","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.l6925"},{"key":"e_1_2_10_10_1","doi-asserted-by":"publisher","DOI":"10.1001\/jamainternmed.2016.8443"},{"key":"e_1_2_10_11_1","doi-asserted-by":"publisher","DOI":"10.1001\/jamainternmed.2016.8471"},{"key":"e_1_2_10_12_1","volume-title":"The Patient and Consumer Voice and Pharmaceutical Industry Sponsorship","author":"Perehudoff S. K.","year":"2011"},{"key":"e_1_2_10_13_1","volume-title":"Determination: Medicines Australia Code of Conduct \u2010 16th Edition","author":"Australian Competition and Consumer Commission","year":"2009"},{"key":"e_1_2_10_14_1","volume-title":"Code of Conduct \u2010 17th Edition","author":"Medicines Australia","year":"2012"},{"key":"e_1_2_10_15_1","doi-asserted-by":"publisher","DOI":"10.1177\/0020731418823376"},{"key":"e_1_2_10_16_1","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pmed.0040296"},{"key":"e_1_2_10_17_1","unstructured":"Medicines Australia \u201cPatient Organisation Support Reports \u201daccessed October 2025 https:\/\/www.medicinesaustralia.com.au\/code\/transparency\u2010reporting\/health\u2010consumer\u2010organisation\u2010support\u2010reports\/."},{"key":"e_1_2_10_18_1","unstructured":"Therapeutic Goods Administration \u201cAustralian Register of Therapeutic Goods (ARTG) \u201daccessed May 2025 https:\/\/www.tga.gov.au\/resources\/artg."},{"key":"e_1_2_10_19_1","volume-title":"Data From \u201cPharmaceutical Industry Payments to Australian Patient Groups: January 2013 to December 2022\u201d","author":"Hooimeyer A.","year":"2026"},{"key":"e_1_2_10_20_1","unstructured":"Australian Charities and Not\u2010for\u2010profits Commission \u201cCharity Register \u201daccessed February 2025 https:\/\/www.acnc.gov.au\/charity\/charities."},{"key":"e_1_2_10_21_1","unstructured":"Reserve Bank of Australia \u201cInflation Calculator \u201daccessed April 2025 https:\/\/www.rba.gov.au\/calculator\/."},{"key":"e_1_2_10_22_1","unstructured":"The jamovi project \u201cjamovi. V. 2.6.44 Released March 6 2025 \u201dhttps:\/\/www.jamovi.org."},{"key":"e_1_2_10_23_1","unstructured":"ViiV Healthcare \u201cThe NGOs and Patient Advocacy Groups We Fund \u201daccessed October 2025 https:\/\/viivhealthcare.com\/corporate\u2010ethics\u2010compliance\/ngos\u2010patient\u2010advocacy\u2010groups\u2010we\u2010fund\/."},{"key":"e_1_2_10_24_1","volume-title":"Indivior"},{"key":"e_1_2_10_25_1","unstructured":"Teva Pharmaceuticals \u201cGlobal Patient Advocacy Engagement \u201daccessed October 2025 https:\/\/www.tevapharm.com\/our\u2010impact\/global\u2010patient\u2010advocacy\u2010engagement\/."},{"key":"e_1_2_10_26_1","unstructured":"Camurus \u201cTransparency Reporting \u201daccessed October 2025 https:\/\/www.camurus.com\/sustainability\/transparency\u2010reporting\/."},{"key":"e_1_2_10_27_1","unstructured":"Kyowa Kirin \u201cTransfer of Value Reporting \u201daccessed October 2025 https:\/\/www.kyowakirin.com\/australia\/transfer_of_value_reporting\/index.html."},{"key":"e_1_2_10_28_1","unstructured":"CSL Seqirus \u201cDisclosures \u201daccessed October 2025 https:\/\/www.cslseqirus.com.au\/our\u2010company\/corporate\u2010responsibility\/disclosures."},{"key":"e_1_2_10_29_1","unstructured":"Grifols \u201cTransparency Disclosures \u2013 Australia \u201daccessed October 2025 https:\/\/www.grifols.com\/en\/australia1."},{"key":"e_1_2_10_30_1","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.l6694"},{"key":"e_1_2_10_31_1","doi-asserted-by":"publisher","DOI":"10.1007\/s00432-024-05889-x"},{"key":"e_1_2_10_32_1","doi-asserted-by":"publisher","DOI":"10.1177\/27551938241305995"},{"key":"e_1_2_10_33_1","doi-asserted-by":"publisher","DOI":"10.1136\/bmjopen-2020-045140"},{"key":"e_1_2_10_34_1","volume-title":"Code of Conduct \u2010 19th Edition","author":"Medicines Australia","year":"2022"},{"key":"e_1_2_10_35_1","volume-title":"Code of Practice \u2010 5th Edition","author":"Generic and Biosimilar Medicines Association","year":"2021"},{"key":"e_1_2_10_36_1","volume-title":"CHP Australia Code of Practice","author":"Consumer Healthcare Products Australia","year":"2022"},{"key":"e_1_2_10_37_1","volume-title":"Code of Conduct \u2010 20th Edition","author":"Medicines Australia","year":"2024"},{"key":"e_1_2_10_38_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.healthpol.2024.105155"},{"key":"e_1_2_10_39_1","unstructured":"Physician Payments Sunshine Act of 2009 42 USC \u00a7 1320a\u20107h."}],"container-title":["Medical Journal of Australia"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.5694\/mja2.70294","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/full-xml\/10.5694\/mja2.70294","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.5694\/mja2.70294","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,10,26]],"date-time":"2026-10-26T04:00:24Z","timestamp":1792987224000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.5694\/mja2.70294"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,10]]},"references-count":38,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2026,10]]}},"alternative-id":["10.5694\/mja2.70294"],"URL":"https:\/\/doi.org\/10.5694\/mja2.70294","archive":["Portico"],"relation":{},"ISSN":["0025-729X","1326-5377"],"issn-type":[{"value":"0025-729X","type":"print"},{"value":"1326-5377","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,10]]},"assertion":[{"value":"2025-12-29","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2026-08-17","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2026-10-04","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}],"article-number":"e70294"}}